Macrogenics (MGNX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

MacroGenics to Participate in Upcoming Investor Conference
GlobeNewswireDec 2, 2024 16:30 ET
MacroGenics Announces Leadership Transition in Financial Roles
TipRanksNov 21, 2024 16:55 ET
Express News | Macrogenetics Dips in Volume Surge, Last Down 6.5%
ReutersNov 13, 2024 14:35 ET
JMP Securities Maintains Macrogenics(MGNX.US) With Hold Rating
Moomoo NewsNov 8, 2024 04:33 ET · Ratings
MacroGenics Downgraded to Market Perform by JMP, Price Target Removed
Seeking AlphaNov 7, 2024 10:51 ET · Ratings
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights
BenzingaNov 7, 2024 10:00 ET

Comments

Trytosaveabit

Nov 5, 2024 18:30

Allow me to break it down! This is what most will see tomorrow! Well the broad strokes anyways! Hehehe

$Macrogenics (MGNX.US)$ Financial Performance:
MacroGenics reported a significant increase in Q2 2024 revenue of $110.7 million, compared to $10.4 million in the same quarter the previous year.
Net income for the quarter was $56.3 million, significantly higher than the $17.6 million recorded in Q3 2023.
The financial improvements were largely due to a $100 million milestone payment from Incyte, a...

8

Trytosaveabit

Nov 5, 2024 15:18

New 8K ( earning & updates )

$Macrogenics (MGNX.US)$ Any that are interested! I advise reading Doc 2 in that new 8K! Could be a very interesting upcoming catalyst before EOY! Hehehe

1

Trytosaveabit

Nov 5, 2024 15:02

Nice

$Macrogenics (MGNX.US)$ Reuters· just
MacroGenics Q3 Net Income USD 56.3 Million Vs. IBES Estimate USD 11.2 Million

1

Jaguar8

Nov 5, 2024 15:02

NEWS ER

$Macrogenics (MGNX.US)$
Positive
▪️Revenue increased significantly to $110.7M from $10.4M YoY
▪️Net income grew to $56.3M from $17.6M YoY
▪️Strong cash position of $200.4M
▪️Secured $100M milestone payment from Incyte
▪️Pending MARGENZA sale for $40M upfront plus up to $35M in milestones
Negative
▪️R&D expenses increased to $40.5M from $30.1M YoY
▪️SG&A expenses rose to $14.1M from $12.4M YoY
▪️Paused development efforts in alternative tumor types for vobra duo

1

Teddy123

Oct 22, 2024 06:37

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

$Macrogenics (MGNX.US)$
22/10/2024 - 19:30
ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)-- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain ma...

MGNX Macrogenics

Trade Overview

Capital Trend

News

Comments

Trending Stocks